Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk (CPSE:NOVO B) reported that its phase 3 HIBISCUS trial of etavopivat for sickle cell disease met both co primary endpoints. The investigational therapy reduced vaso occlusive crisis events and improved haemoglobin response in trial participants. The company plans to submit etavopivat for regulatory approval in the second half of 2026. Novo Nordisk, widely associated with diabetes and obesity treatments, is using etavopivat to expand into blood disorders. For investors, sickle cell disease represents a different therapeutic area to watch, with a patient population that faces significant unmet medical needs and limited treatment options. This phase 3 readout gives CPSE:NOVO B another late stage asset that sits outside its core metabolic portfolio. Looking ahead, the planned regulatory submission in 2026 represents a potential new chapter for Novo Nordisk's pipeline mix. Developments for etavopivat, alongside recent news about a rival therapy, may inform how you ass
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind [Seeking Alpha]Seeking Alpha
- Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal [Yahoo! Finance]Yahoo! Finance
- Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals stock tumbles 25% after Novo data [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website